Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Industry / Japan

A New 'Drug Lag' Record

August 2008 | Product Launch

The cautious nature of Japan's regulatory regime has been demonstrated once again. A government panel has recommended approval of thalidomide for multiple myeloma ten years after it was registered in the US for this new indication. While BMI applauds Japan's commitment to patient safety, the bureaucracy it imposes on the regulatory system means that innovative therapeutics are not reaching the market quickly enough.

Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.

[
: *
[
: *

Forgotten your password?

If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.

Free Trial To Pharmaceuticals & Healthcare Insight

TAKE A TRIAL >>
Related Insight Articles
Abbott Expects To Outperform Market

Industry / Japan Following the launch of its breakthrough rheumatoid arthritis therapeutic, US drugmaker Abbott Laboratories is looking to outperform the Japanese patented drug sector over the next two years. By 2010,...
June 2008
Mylan Announces Generic Sector Assault

Industry / Japan Another drugmaker has outlined an aggressive strategy to penetrate Japan's booming generic drug sector, confirming the trend that has emerged over the last six months. US-based Mylan Laboratories will...
March 2008
Healthcare Budget Raised

Industry / Japan On the back of relatively strong economic growth in 2007, Japan has increased the amount it will spend on healthcare during 2008. BMI tends to welcomes such rises, but in this instance it may not be...
January 2008
Japanese Drugmakers Wary Of Takeover Threat

Companies / Japan Rather than sitting on excess funds, Japan's major drugmakers are using profit windfalls to repurchase shares. Although these companies claim that they are merely trying to utilise their capital in an...
October 2006
Japan's Kyowa Hakko Invests In Antibodies

Companies / Japan Japanese pharmaceutical company Kyowa Hakko Kogyo is to invest some US$27mn on a new GMP-compliant animal cell culture unit. The expansion to the Fuji manufacturing facility is expected to begin in...
July 2006


All material on this site is protected by international copyright laws and use of this site is subject to our Terms & Conditions.
© 2009 Business Monitor International Ltd
Site powered by WORKSsitebuilder CMS